Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.
Breaking News:
- Savoye appoints Hakim Ramadan to lead Middle East expansion amid accelerating logistics growth
- Dubai Chamber of Commerce organises seminar to strengthen logistics cooperation between Dubai and Oman with representatives of more than 360 companies
- Object 1 marks Abu Dhabi entry with launch of A1LA Residence on Al Reem Island
- 62% of Saudi leaders are failing to use their data effectively, New Cloudera Report Finds
- beIN SPORTS SECURES RIGHTS TO FIA WORLD ENDURANCE CHAMPIONSHIP ACROSS 35 TERRITORIES
- TheBlueWhale.ai announces new course ‘Top 12 AI Tools to Boost Your Productivity’.
- Mashreq Partners with Toothpick to Launch UAE’s First Digital Loan Solution for Healthcare Services
- 42% of CFOs plan to increase AI investment by over 30% within two years—Bain & Company
Thursday, April 16